Joint space width all x-rays, joint space narrowing (JSN) x-rays available for valid assessment of structural disease progression, mean (SD) JSW and JSN, 95% CI difference with placebo
| Placebo | Glucosamine | Glucosamine–chondroitin | Chondroitin | |
|---|---|---|---|---|
| Joint space width | ||||
| Baseline, mm (SD) | 3.81 (0.96) n=151 | 3.78 (1.06) n=152 | 3.81 (0.95) n=151 | 3.71 (0.97) n=151 |
| Year 1, mm (SD) | 3.75 (1.03) n=127 | 3.70 (1.18) n=131 | 3.76 (0.96) n=132 | 3.61 (1.00) n=129 |
| Year 2, mm (SD) | 3.70 (1.04) n=121 | 3.62 (1.22) n=125 | 3.80 (1.03) n=121 | 3.63 (1.06) n=117 |
| Joint space narrowing | ||||
| Available x-ray sets*, n (%) | ||||
| 1-year follow-up only | 40, 26% | 52, 34% | 55, 36% | 47, 31% |
| 2-year follow-up | 80, 53% | 76, 50% | 74, 49% | 73, 48% |
| 1- and 2-year follow-up | ||||
| n (%) | 120 (79%) | 128 (84%) | 129 (85%) | 120 (79%) |
| JSN, mm (SD) | 0.18 (0.29) | 0.21 (0.33) | 0.12 (0.27) | 0.18 (0.29) |
| Difference to placebo (95% CI) | 0.03 (−0.04 to 0.11) | −0.06 (−0.14 to 0.01) | 0.00 (−0.08 to 0.08) | |
| Adjusted† | 0.02 (−0.05 to 0.10) | −0.06 (−0.14 to 0.01) | −0.01(−0.09 to 0.07) | |
| 2-year follow-up | ||||
| n (%) | 80 (53%) | 76 (50%) | 74 (49%) | 73 (48%) |
| JSN, mm (SD) | 0·22 (0·33) | 0·24 (0·37) | 0·12 (0·25) | 0·20 (0·32) |
| Difference to placebo (95% CI) | 0.03 (−0.07 to 0.13) | −0.10 (−0.20 to 0.00) | −0.01 (−0.11 to 0.09) | |
| Adjusted† | 0.01(−0.09 to 0.11) | −0.10 (−0.20 to 0.00) | −0·03 (−0.13 to 0.07) | |
| n/N (%) | ||||
| 2-year JSN ≥7% | 23/80 (29%) | 24/76 (32%) | 16/74 (22%) | 20/73 (27%) |
| 2-year JSN ≥0.5 mm | 11/80 (14%) | 14/76 (18%) | 6/74 (8%) | 10/73 (14%) |
*Available x-ray sets: <1.7 mm medial tibial inter-rim distance, <0.2 mm difference in tibial inter-rim distance between baseline and follow-up x-ray.
†Adjusted for gender, baseline BMI, baseline tibio-femoral joint space width, KL grade and presence of Heberden's nodes using multiple regression model.
BMI, body mass index; JSW, medial tibio-femoral joint space width.